MARKET NEWS

WPD Pharmaceuticals’ New Discovery for Cancer Targeting Drugs is Granted Patent
Oxford BioTherapeutics Initiates Dose-Escalation Portion of Phase I Clinical Trial
Zai Lab & Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial
TYME Announces First Patient Dosed in Pivotal Trial 
Bayer Exercises Right to Enter Follow-On Research & Collaboration Option Agreement
ArTara Therapeutics Completes Merger Transaction With Proteon Therapeutics

  FEATURED EDITORIAL

  COMPANY PROFILE

Pharmaceutical formulators continue to strive to create market leading products with maximum efficacy, quality, and performance. However, the inability to achieve a high level of API solubility and stability are common day-to-day challenges which limit product success. With the help from Croda’s superior quality and high purity line of specialty excipients, formulators are able to surpass these barriers, making Croda the supplier of choice in the global pharmaceutical market. With products being manufactured at multiple sites throughout the world, we are able to provide a consistent, local supply of a vast range of high purity surfactants, lipids, and other chemical specialties. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Nurix Therapeutics & Sanofi Establish Strategic Collaboration 

Nurix Therapeutics & Sanofi Establish Strategic Collaboration 

Nurix Therapeutics, Inc. recently announced a global strategic collaboration with Sanofi to discover, develop, and commercialize a pipeline of innovative targeted protein….

Catalent Completes Purchase of Biologics Fill-Finish & Oral Solid Dose Facility in Anagni, Italy

Catalent Completes Purchase of Biologics Fill-Finish & Oral Solid Dose Facility in Anagni, Italy

Catalent recently announced the completion of the purchase of Bristol-Myers Squibb’s biologics, sterile, and oral solid dose product manufacturing and packaging facility….

Sebia Enters Development Agreement With Sanofi

Sebia Enters Development Agreement With Sanofi

Sebia recently announced it is entering into an agreement with Sanofi to develop an in vitro diagnostic (IVD) test that mitigates the potential interference caused by……

HIGH PURITY EXCIPIENTS - A Simple Solution to a Complex Problem

William Small, PhD, and Arsalan Khan say drug degradation can have toxicological effects in many instances, and it is imperative that this mechanism be minimized as much as possible. The best solution to this is to ensure that appropriate ingredients, both high in quality and purity, are chosen and used throughout the entire drug product lifecycle.

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

January 22 – Drug Delivery
January 29 – Bioavailability